Recursion Pharmaceuticals, Inc. RXRX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s operating cash flow?
- Recursion Pharmaceuticals, Inc. (RXRX) reported operating cash flow of -$81.1M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s operating cash flow changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s operating cash flow increased by 38.5% year-over-year, from -$131.96M to -$81.1M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s operating cash flow has grown at a 23.7% compound annual growth rate (CAGR), from -$158.61M to -$371.81M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.